Consistent with a previous infection of these individuals, we found a statistically significant increase of circulating SARS-CoV-2–specific IgG and IgA antibodies against S2+RBD in anti-NP+ MM patients compared with the anti-NP− counterparts (P = 0.003 and P = 0.04, respectively, Fig 1A and B). The gene discussed is CD79A; the disease is infection.